GO
Loading...

Roche Holding AG

More

  • Stocks End Sharply Higher After Fed News Wednesday, 25 Jan 2012 | 7:57 PM ET

    Stocks ended near session highs Wednesday, reversing their early declines, as the market cheered news that the Fed will not raise interest rates until at least 2014 in addition to maintaining its highly accommodative stance to support the recovery.

  • Finerman’s Fine Print: Roche Hostility Wednesday, 25 Jan 2012 | 6:29 PM ET

    Illumina landed squarely on Karen Finerman’s trader radar Wednesday with the company in the cross hairs of a hostile bid from Roche.

  • Roche Makes $5.7B Bid for Illumina     Wednesday, 25 Jan 2012 | 5:21 PM ET

    Keith Moore, MKM Partners, discusses how to play Roche's hostile bid for gene sequencer, Illumin, saying ILMN is likely to fight the takeover. Also an update on SanDisk's earnings, with the Fast Money crew.

  • Finerman's Fine Print: Roche Hostility     Wednesday, 25 Jan 2012 | 5:18 PM ET

    Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.

  • CNBC's David Faber has the details on Roche's Illumina offer worth $44.50 per share in cash.

  • Futures Mixed Ahead of Fed; Apple Surges Wednesday, 25 Jan 2012 | 9:17 AM ET

    U.S. stock index futures struggled for direction Wednesday as investors digested a handful of corporate earnings and ahead of the Federal Reserve's policy statement.

  • Roche CEO: Sales Hit By Strong Swiss Franc     Thursday, 13 Oct 2011 | 3:30 AM ET

    Severin Schwan, CEO of Roche, made his first appearance on CNBC, to discuss the pharmaceutical giant's third quarter earnings.

  • Roche to Miss on Avastin Guidance?     Friday, 7 Oct 2011 | 12:00 PM ET

    Swiss pharmaceutical giant, Roche, is due to release its Q3 sales results on Thursday. Amit Roy, head of healthcare equity research at Nomura and Barath Subramanian, healthcare senior consultant at Frost & Sullivan, joined CNBC to discuss what we can expect, and how the pharmaceutical sector as a whole is holding up.

  • FDA Approves Roche Skin Cancer Drug Zelboraf Wednesday, 17 Aug 2011 | 2:55 PM ET

    U.S. drug regulators approved a targeted skin cancer drug from Roche Holding, offering new hope for patients with the deadliest form of cancer after years of few options.

  • FDA & Avastin's Future     Tuesday, 28 Jun 2011 | 11:15 AM ET

    The fate of the world's best-selling cancer medicine is in the hands of the FDA. There's a lot at stake for Roche and the thousands of women who take the drug, reports CNBC's Hampton Pearson.

  • Cancer: The Business of Hope     Monday, 6 Jun 2011 | 11:20 AM ET

    A look at how Roche has recently received a boost from regulators for its key medications, with Hal Barron, Roche chief medical officer.

  • DNA Testing Spurring New Breed of Cancer Drugs Monday, 6 Jun 2011 | 9:37 AM ET

    These more targeted, or niche,  drugs might only treats thousands, but they could yield higher success rates for patients and lower marketing costs for the industry.

  • Roche's Avastin Still Growth Driver: CEO Thursday, 14 Apr 2011 | 7:46 AM ET

    Roche's cancer drug Avastin remains a growth driver for the company despite disappointing sales in the US and Europe as a result of regulatory restrictions, Chief Executive Severin Schwan told CNBC on Thursday.

  • 7 Best Value Picks for Investors: Pros Thursday, 10 Mar 2011 | 10:27 AM ET

    With the markets on a decline, investors need to put money into value plays, said Rob Hoxton, president and CEO of Hoxton Financial, and Robert Auer, portfolio manager at Auer Growth Fund.

  • Stocks Will Move Higher in First Half of 2011: Pro Thursday, 20 Jan 2011 | 12:27 PM ET

    Markets are probably due for a pullback in the near-term, but for the first half of 2011, stock are going to move higher, said Andrew Kanaly, chairman of Kanaly Trust Company.

  • Europe Stocks Seen Unchanged After EU Decision Friday, 17 Dec 2010 | 2:04 AM ET
    Trader at London Stock Exchange, England.

    European shares are expected to open flat Friday, though concerns about the euro zone debt crisis linger and could weigh on markets.

  • FDA Rejects Qnexa, a Third Weight-Loss Drug Friday, 29 Oct 2010 | 4:32 AM ET

    The Food and Drug Administration rejected another new diet pill on Thursday, the latest setback in the quest to develop treatments for overweight Americans amid the nation’s obesity epidemic.

  • Amylin, Lilly and Alkermes Volatile All Week? Monday, 8 Mar 2010 | 5:53 PM ET

    A handful of biopharma stocks could be pretty volatile this week and we're talking right up until Friday.

  • Will Deal Making Keep Floor Under Market? Monday, 1 Mar 2010 | 5:24 PM ET

    Deal making is officially back on with three major takeovers announced Monday. Where is the Fast Money finding alpha amid increasing acquisitions?

  • Results of a new study could change the way elderly patients with vision trouble are treated and have financial implications for Swiss drug giants Novartis and Roche.

Most Popular Video

Wednesday, 23 Apr 2014 | 4:57 PM ET

Weekly jobless claims and durable goods are the numbers to watch Thursday, but so are the massive amount of earnings reports expected. CNBC's Patti Domm explains.

Wednesday, 23 Apr 2014 | 4:32 PM ET

Apple is reporting Q2 EPS of $11.62 on revenue of $45.6 billion. Gene Munster, Piper Jaffray senior research analyst, says investors should feel a sense of relief on these numbers.

Wednesday, 23 Apr 2014 | 3:23 PM ET

CNBC's Becky Quick discusses Warren Buffett's feelings about the market.